Review article: strategies for the management of chronic unremitting ulcerative colitis
Alimentary Pharmacology & Therapeutics2013Vol. 38(2), pp. 77–97
Citations Over TimeTop 10% of 2013 papers
Abstract
No current pharmacological treatment delivers mucosal healing in the majority of patients. Newer treatments such as vedolizumab and tofacitinib may represent valuable future therapies. Available medical options should be discussed with patients at every step of their management, with an honest appraisal of the evidence. Surgery should always be considered in patients with chronic refractory disease of any extent.
Related Papers
- → Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology(2022)44 cited
- → Biological therapy for ulcerative colitis: An update(2014)28 cited
- → The Toronto Consensus Guidelines for Nonhospitalized Ulcerative Colitis: A Welcome Update but Not the End of the Story(2015)2 cited
- Biologic drugs for inflammatory bowel disease.(2017)
- Biological therapy for ulcerative colitis:An update(2014)